Gemmothérapie Rate Pancreas / Pi complément alimentaire
Food supplement declared in France, declaration No 2020-6-26, decision dated 1 June 2020
Gemmothérapie Rate Pancreas / Pi complément alimentaire (MERYSTEME) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Betula pubescens 287 mg per day, Morus nigra 287 mg per day, Vaccinium myrtillus 287 mg per day, Juglans regia 287 mg per day, Rubus fruticosus 287 mg per day. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- MERYSTEME
- Food business operator placing the product on the market
- MERYSTEME
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Bottle
- Daily dose
- 30 gouttes
- Directions for use
- 5 à 15 gouttes 2 fois par jour dans un verre d'eau pendant 21 jours
- Not recommended (according to the manufacturer)
- Allergy to salicylate derivatives, Taking anticoagulants
Declaration 316345, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Betula pubescens Ehrh. | Bourgeon | Autre extrait fluide | 287 mg |
| Morus nigra L. | Feuille (bourgeon) | Autre extrait fluide | 287 mg |
| Vaccinium myrtillus L. | Jeune pousse | Autre extrait fluide | 287 mg |
| Juglans regia L. | Bourgeon | Autre extrait fluide | 287 mg |
| Rubus fruticosus L. | Jeune pousse | Autre extrait fluide | 287 mg |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
L'emploi aux personnes allergiques aux dérivés salicylés et aux personnes sous traitements anticoagulant est déconseillé. Tenir hors de portée des enfants.
Regulatory points
- Conditions légales
Betula pubescens Ehrh.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux personnes souffrant d'allergie aux dérivés salicylés
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Betula pubescens Ehrh.
Read the warning, when it applies and the studies cited
Birch
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney or cardiovascular disorders (Brinker 2010; Bradley 2006; ESCOP 2003; Blumenthal et al. 1998).
Sources cited by Health Canada (4)
- Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Riggins C, Rister R, editors. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin (TX): American Botanical Council; 1998.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Vaccinium myrtillus L.
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : MERYSTEME
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Gemmothérapie Rate Pancreas / Pi complément alimentaire (MERYSTEME): composition and regulation”, https://compoatlas.com/en/supplements/products/316345-gemmotherapie-rate-pancreas-pi-complement-alimentaire, updated 15 November 2026.